I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $389.46M

Company

Location

Date

Amt. (M)

Details


Amaxa GmbH

Cologne,
Germany

6/13

EUR13
(US
$11.6)

Amaxa completed its second financing round; investors included 3i Group Investments LP, NRW Fonds GmbH and Technomedia Kapitalbet-
eiligungsgesellshaft Koln mbH

Amedis
Pharmaceuticals

UK

6/13

#4
(US
$5.56)

Amedis raised US$5.56M; investors included Merlin Biosciences Ltd., Avlar BioVentures Fund I, TTP Venture Fund and Andy Richards

Biophage Inc.

Montreal

6/20

C$2.6
(US
$1.7)

Biophage raised US$1.7M in a placement with Quebec and offshore investors

Biophage Inc.

Montreal

6/27

C$0.85
(US
$0.56)

Biophage completed a private placement representing about 1.4M units priced at C60 cents per unit; the financing was part of a letter of intent signed in April between the controlling shareholders of the company and Almont Capital Corp.

Biovitrum AB

Stockholm,
Sweden

6/11

$130

Biovitrum raised $130M in a seed financing; investors included MPM Capital LP, Nordic Capital, MPM BioEquities, Karolinska Investment, ABN-AMRO Ventures, Carnegie Asset Management, H&B Capital and Next Gear

Corcept
Therapeutics
Inc.

Menlo Park,
Calif.

6/20

$27

Corcept raised $27M in its Series C financing, which included investors Sutter Hill Ventures, Alta Partners and Maverick Capital

Corus Pharma
Inc.

Seattle

6/6

$18.5

Corus raised $18.5M in its Series A financing round; investors included Burrill & Co., Cascade Investment, JP Morgan Partners and Orbimed Advisors

Cyclacel Ltd.

Dundee, UK

6/14

#34
(US
$47.6)

Cyclacel completed a US$47.6M Series C placement led by INVESCO Private Capital

Cytomation
Inc.

Fort Collins,
Colo.

6/6

$14

Cytomation closed a $14M private placement with undisclosed U.S. and international investors

Genicon
Sciences Corp.

San Diego

6/6

$5

Genicon completed a $5M second closing in its Series D financing

Guava
Technologies
Inc.

Burlingame,
Calif.

6/21

$17.5

Guava raised $17.5M in its second round of venture financing, led by ProQuest Investments LP and Abingworth Management Ltd.; other investors were Paul Venture Capital, Skyline Ventures and Fog City Fund

Ichor Corp.

Lyon, France

6/18

$2

Ichor completed a $2M private financing from a consortium of investors advised by MFC Merchant Bank

IntegraGen

Evry, France

6/21

EUR6.3
(US
$5.4)

IntegraGen raised US$5.4M in its first financing round; investors were CDC Innovation 2000, GenAvent, BioAm and Bay Tech

Kourion
Therapeutics

Dusseldorf,
Germany

6/28

EUR12
(US
$10.3)

MPM Capital LP's BioVentures II group of funds acquired a major ownership stake in Kourion

Medgenics
Inc.

Misgav,
Israel

6/20

$7

Medgenics completed a Series A financing of $7M that included Alta Partners, Koor Corporate Venture Capital and Alta Berkeley Venture Partners

Neurogenetics
Inc.

San Diego

6/25

$9

Neurogenetics raised $9M in its Series B financing; investors included Advent International Corp., Alta Partners, GIMV, Novartis Venture Fund and S.R. One

NeuroSearch
A/S

Ballerup,
Denmark

6/21

DKK
128.6
(US
$14.7)

NeuroSearch completed a private placement to a limited number of Danish and international investors

NitroMed
Inc.

Bedford,
Mass.

6/14

$31.4

NitroMed raised $31.4M in a round led by Rho Ventures; other investors were Care Capital LLC, Morgan Stanley Venture Partners and Quintiles Transnational Corp., as well as HealthCare Ventures, Boston University's Community Technology Fund and Johnson & Johnson Development Corp.

Screentec
BV

Leiden, the
Netherlands

6/13

EUR6.5
(US
$5.54)

Screentec raised US$5.54M in its first round of financing; investors included Life Science Partners, Prelude Trust and Alafi Capital

Sterix Ltd.

Oxford, UK

6/20

#8
(US
$11.1)

Sterix raised US$11.1M through a private financing

VitaGen
Inc.

La Jolla,
Calif.

6/28

$14

VitaGen raised $14M in the first closing of its Series C financing; investors were JP Morgan Partners, BD Ventures, Merrill Lynch Ventures, Perseus Biotech Advisors, Tullis-Dickerson & Co., Essex Woodlands Health Ventures, Pacific Horizon Ventures, Paragon Venture Partners II, Alta Partners, Radius Ventures, Triad Ventures Ltd. II, BCM Technologies, Orbitex Management, Banc One Venture Partners and CDIB U.S. Biotech

II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS

FROM EXISTING CORPORATE PARTNERS: $11.2M

Company
(Symbol)#*

Partner
(Country)

Amt.
(M)

Triggering Event

Details (Date)


Acambis plc
(UK; ACAM;
LSE:ACM)

Baxter
International
Inc.

#3.5
(US
$4.8)

Equity
investment

Acambis received the second tranche of an equity investment from Baxter, as agreed when the two set up a vaccines collaboration last year (6/13**)

Atrix
Laboratories
Inc.
(ATRX)

Sanofi-Synthelabo
(France)

$3

Milestone
payment

Atrix received a $3M milestone payment for filing an NDA for Leuprogel One-Month Depot to treat advanced prostate cancer (6/26)

BioMimetic
Pharmaceuticals
Inc.*

Novo A/S (unit
of Novo Group)

ND

Investment

BioMimetic received an investment from Novo A/S (6/26)

Entelos Inc.*

R.W. Johnson
Pharmaceutical
Research Institute
(subsidiary of
Johnson &
Johnson)

ND

Milestone
payment

Entelos developed a PhysioLab disease simulation system for Type II diabetes, marking a milestone in the companies' partnership (6/22)

Genome
Therapeutics
Corp.
(GENE)

American Home
Products Corp.

ND

Milestone
payment

Genome received a milestone payment from Wyeth-Ayerst, the pharmaceutical division of American Home Products (6/18)

GPC Biotech
(Germany;
FSE:GPC)

Byk Gulden
(unit of
Altana AG)

ND

Milestone
payment

Company achieved a milestone by delivering seven targets in its antimicrobial alliance (6/27)

ImClone
Systems Inc.
(IMCC)

Merck KGaA
(Germany)

$0.5

Milestone
payment

ImClone received a $500,000 milestone payment for the randomization of patients in a Phase III trial of BEC2 in small-cell lung carcinoma (6/18)

Ligand
Pharmaceuticals
Inc.
(LGND)

Wyeth-Ayerst
Laboratories
(division
of American
Home Products
Corp.)

ND

Milestone
payment

Ligand initiated Phase III trials of TSE-424, triggering the milestone payment (6/22)

MediGene
AG
(Germany;
Neuer
Markt:MDG)

Aventis Pharma
AG
(Germany)

DM2
(US
$0.9)

MIlestone

payment

MediGene received a US$878,149 milestone payment for initiating a Phase I/II trial for a vaccine against malignant melanoma (6/25)

Metabometrix
Ltd.
(UK)*

Gene Logic Inc.

ND

Equity
investment

Gene Logic made an equity investment in Metabometrix, concurrent to the initiation of a research collaboration (6/14)

Orchid
BioSciences
Inc.
(ORCH)

AstraZeneca
(UK)

ND

Milestone
payment

Orchid achieved a milestone in its multiyear genotyping and pharmacogenetics collaboration, triggering a payment (6/29)

Quark Biotech
Inc.*

Fujisawa
Pharmaceutical
Co. (Japan)

ND

Equity
investment

Quark received an equity investment as part of its Series F financing (6/27)

StemCells Inc.
(STEM)

Millennium Partners
LP

$2

Equity
investment

Millennium exercised an option to purchase

457,750 shares of StemCells for $2M (6/22)

Vernalis
Group plc
(UK;
LSE:VER)

F. Hoffmann-La
Roche
Ltd. (Switzerland)

ND

Milestone
payment

Vernalis selected a lead clinical candidate from its collaboration in obesity, triggering the milestone payment (6/12)

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Denotes privately held company.

** Denotes the date the item ran in BioWorld International.

ND = Not disclosed

FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange

No Comments